These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 23075808)

  • 1. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
    Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
    Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma.
    Kipriyanov SM; Cochlovius B; Schäfer HJ; Moldenhauer G; Bähre A; Le Gall F; Knackmuss S; Little M
    J Immunol; 2002 Jul; 169(1):137-44. PubMed ID: 12077238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
    Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
    Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
    Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
    Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
    Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
    Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.
    Altvater B; Landmeier S; Pscherer S; Temme J; Schweer K; Kailayangiri S; Campana D; Juergens H; Pule M; Rossig C
    Clin Cancer Res; 2009 Aug; 15(15):4857-66. PubMed ID: 19638467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
    Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
    Tay SS; Carol H; Biro M
    Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
    Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
    Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
    Gantke T; Weichel M; Herbrecht C; Reusch U; Ellwanger K; Fucek I; Eser M; Müller T; Griep R; Molkenthin V; Zhukovsky EA; Treder M
    Protein Eng Des Sel; 2017 Sep; 30(9):673-684. PubMed ID: 28981915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells.
    Aste-Amezaga M; D'Andrea A; Kubin M; Trinchieri G
    Cell Immunol; 1994 Jul; 156(2):480-92. PubMed ID: 7912999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.
    Felices M; Lenvik TR; Davis ZB; Miller JS; Vallera DA
    Methods Mol Biol; 2016; 1441():333-46. PubMed ID: 27177679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of a novel bispecific protein ULBP1×CD19-scFv targeting the NKG2D receptor and CD19 to promote the activation of NK cells.
    Zhao Q; Pang J; Yan F; Jiang Y; Cui D; Liu J; Jing L; Li Y; Liu Z; Tao L; Zhao X; Diao A
    Protein Expr Purif; 2021 Feb; 178():105783. PubMed ID: 33122138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
    Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
    Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
    Sahin U; Kraft-Bauer S; Ohnesorge S; Pfreundschuh M; Renner C
    Cancer Immunol Immunother; 1996 Jan; 42(1):9-14. PubMed ID: 8625370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16.
    Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M
    Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC.
    van Faassen H; Jo DH; Ryan S; Lowden MJ; Raphael S; MacKenzie CR; Lee SH; Hussack G; Henry KA
    Mol Pharm; 2021 Jun; 18(6):2375-2384. PubMed ID: 33999642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.